A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair-proficient (MMR-P) recurrent or persistent endometrial cancer (EC)-MedSci.cn

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair-proficient (MMR-P) recurrent or persistent endometrial cancer (EC)

Lee, EK; Xiong, NY; Cheng, SC; Polak, M; Krasner, CN; Campos, SM; Wright, AA; Liu, JF; Shea, M; Yeku, OO; Castro, CM; Porter, RL; Stover, E; Bouberhan, S; Moroney, JW; Penson, RT; Fleming, GF; Matulonis, UA; Konstantinopoulos, PA

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务